Ertam, İlgenSu, ÖzlemAlper, SibelSarıcaoğlu, HayriyeKaradağ, Ayşe SerapDemirsoy, Evren OdyakmazBorlu, Murat2024-10-162024-10-162018-01-011019-214Xhttps://doi.org/10.4274/turkderm.87143https://jag.journalagent.com/turkderm/pdfs/TURKDERM_52_1_6_23.pdfhttps://hdl.handle.net/11452/46519Background and Design: Atopic dermatitis (AD) has a complicated etiopathogenesis and difficulties in diagnosis and treatment from time to time. Because of the disease which different approaches can be seen rationalize the need for an algorithm for the diagnosis, classification, etiopathogenesis, diagnostic tests and therapeutic approach. Therefore, authors from Dermatoallergy Working Group of the Turkish Society of Dermatology aimed to create an AD guideline for the diagnosis, treatment and followup.Materials and Methods: Each section of the guideline has been written by a different author. The prepared sections were evaluated in part by e-mail correspondence and have taken its final form after revision in the last meeting held by the participation of all authors.Results: The guideline includes the diagnosis, classification, etiopathogenesis, diagnostic tests and therapeutic approach of AD. Lesions show age-related morphology and distribution. There are no in vivo/in vitro tests that have high sensitivity and specificity that can be used to identify AD and trigger factors. The first step of treatment consists of moisturizers, topical corticosteroids and calcineurin inhibitors, respectively. Moisturizers are used therapeutically in all forms of AD. Topical corticosteroids are the first agents to be used when moisturizers are inadequate. Topical calcineurin inhibitors should be used in lesions resistant to corticosteroids, for proactive treatment, special areas. Antimicrobials agents and antiseptics should only be added to treatment when clinical signs of infection are present. And in topical treatment-resistant cases, second-line treatment is phototherapy or oral cyclosporine. The biologic agent, dupilumab, is promising in the treatment of severe AD.Conclusion: AD is a disease that can be challenging for the physician in terms of treatment and follow-up. Depending on evidence-based data (and individual experiences), this guideline will have a leading role in the diagnosis and treatment of AD and help the physician to overcome the challenges in the management.eninfo:eu-repo/semantics/openAccessThymic stromal lymphopoietinReduce staphylococcus-aureusOf-function mutationsWet-wrap dressingsDouble-blindInterferon-gammaStratum-corneumPosition paperFood allergyBarrier functionAtopic dermatitisAlgorithmGuidelineDiagnosisTreatmentTurkeyScience & technologyLife sciences & biomedicineDermatologyArticle00043579740000362352110.4274/turkderm.871431308-6294